MicroRNAs for the generation of astrocytes
AssigneesExostem Biotec Ltd., Henry Ford Health System
InventorsChaya Brodie, Shimon Slavin
Life of this patent
Estimating the term…
Abstract
A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.
Claims9
An isolated population of genetically modified mesenchymal stem cells (MSCs) differentiated toward an astrocytic phenotype wherein each MSC comprises a combination of an exogenous microRNA (miR)-146 (SEQ ID NO:462) and an antagomir or RNA oligonucleotide that hybridizes to and inhibits an endogenous miR-302 (SEQ ID NO:369), wherein at least 50% of the MSCs express glial fibrillary acidic protein.
A method of generating an isolated population of genetically modified mesenchymal stem cells (MSCs) differentiated toward an astrocytic phenotype, wherein at least 50% of the MSCs express glial fibrillary acidic protein, the method comprising introducing and expressing in MSCs a combination of an exogenous microRNA (miR)-146 (SEQ ID NO:462) and an antagomir or RNA oligonucleotide that hybridizes to and inhibits an endogenous miR-302 (SEQ ID NO:369), thereby generating an isolated population of genetically modified mesenchymal stem cells (MSCs) differentiated toward an astrocytic phenotype.
Dependencies are inferred from the claim text.